723 published test results across 108 vendors · latest: 12 Oct 2026
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | SShanghai ERP peptide Biotechnology Unverified | 13 | $1.59 | 74 |
| 2 | LLisa Biopeptide Unverified | 7 | $1.50 | 65 |
| 3 | ZZePeptide Unverified | 7 | $2.20 | 61 |
| 4 | MMai Peptide Unverified | 7 | $2.20 | 60 |
| 5 | AAllen Biotechnology Co ABC Unverified | 9 | $1.45 | 60 |
| 6 | UUther Unverified | 10 | $1.35 | 60 |
| 7 | SSaiyanMed | 4 | $2.19 | 58 |
| 8 | SShanxi Qianyecao Biotech QYC Unverified | 12 | $1.90 | 58 |
| 9 | YYimei Unverified | 6 | $3.69 | 57 |
| 10 | LLiliPeptide Unverified | 24 | $2.45 | 57 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Tesamorelin is the rare compound here with current FDA approval: as Egrifta, it treats HIV-associated lipodystrophy. Gray-market vials piggyback on that legitimacy while sitting entirely outside its manufacturing and oversight.
Tesamorelin is the fourth most-tested compound in our index, and the record reads strangely uniform: 73 vendors, leader scores packed between 56 and 65, and top-five pricing in a tight $1.35 to $1.90 per milligram band. Tight pricing with middling scores usually means a commodity supply chain, many sellers drawing on similar upstream sources, no one with a record deep enough to stand out. Fresh results run through August 2026, so recency is not the problem here; depth per vendor is, at six to twelve tests each.
Because the approved product is expensive, narrowly indicated, and prescribed for a specific HIV-associated condition, while the gray market sells the same molecule to a different audience entirely: people chasing the visceral-fat findings from its clinical program. A research vial is not Egrifta any more than gray-market semaglutide is Ozempic; the molecule matching its label is exactly what the published batch record exists to check, and nothing else about the pharmaceutical transfers.
It sits in the same research-use-only territory as the rest of this market. The approved version requires a prescription and is dispensed as Egrifta.
Per-vendor records top out around a dozen tests, and our confidence adjustment caps what a shallow record can earn. The scores describe evidence depth as much as batch quality.
Scored vendors cluster at $1.35 to $1.90 per milligram as of September 2026. Prices far outside that band, in either direction, deserve an explanation before an order.
Nothing on this page is medical advice; compounds shown are sold for research purposes only. Data is aggregated from publicly published third-party results and traces to its source.